Novel anti-AD dimeric leads:from relieving symptoms to modifying diseases via multi-targets

作     者：HAN Yi-fan HU Sheng-quan Marvin MAK WANG Jia-jun 

作者机构：State Key Laboratory of Chinese Medicine and Molecular Pharmacology(Incubation)The Hong Kong Polytechnic University Shenzhen Research InstituteShenzhen518045China Department ofApplied Biology and Chemical TechnologyInstitute of Modern Chinese MedicineThe Hong KongPolytechnic UniversityHong KongChina 

出 版 物：《中国药理学与毒理学杂志》 (Chinese Journal of Pharmacology and Toxicology)

年 卷 期：2019年第33卷第6期

页      面：412-412页

学科分类：1002[医学-临床医学] 100203[医学-老年医学] 10[医学] 

基　　金：Poly U(G-YBGQ G-SB81 G-YZ95) the Research Grant Council of Hong Kong(15101014) ITSP-Guangdong-Hong Kong Technology Cooperation Funding Scheme(GHP/012/16GD) Shenzhen Basic Research Program(JCYJ20160331141459373) 

主　　题：Alzheimer disease dimeric leads multi-targets relieving symptoms modifying diseases 

摘      要：Alzheimer disease(AD) has now become the most common brain disorder among the older population. In addition, the currently existing therapeutics only offer temporary symptomatic relieves. Therefore, further research and development of more efficacious and disease-modifying agents for the prevention, treatment and restoration of AD will have tremendous value from both scientific, and economic standpoints. Over the past few years, our series of studies have identified several highly promising anti-AD dimeric leads, with disease-modifying potentials. In this presentation, the latest progress on the neuroprotective and disease modifying effects and the underlying mechanisms of those candidates will be comprehensively illustrated and discussed.